Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY rallied 1.86% to $50.94 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.25% to 5,732.93 and the Dow Jones Industrial Average DJIA rising 0.20% to 42,208.22. This was the stock's third consecutive day of gains.
What Analysts Are Saying About Bristol-Myers Squibb Stock
In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 0.26% from the previous average price target of $45.88.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been facing a few challenges for quite some time now.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY shed 1.00% to $49.49 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18. The stock's fall snapped a two-day winning streak.
With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
4h
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
1d
Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data
BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...
Pharmaceutical Technology
1d
Bristol-Myers Squibb gets grant for method for dosing treatment in systemic lupus erythematosus
Discover Bristol-Myers Squibb's groundbreaking patent for personalized SLE treatment, utilizing IKZF3 gene expression to optimize dosage for better patient outcomes.
insurancebusinessmag
8d
Bristol-Myers faces lawsuit over $2 billion pension risk transfer to Athene
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
FiercePharma
4d
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers ...
STAT
10d
Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and ...
BioSpace
1d
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
FiercePharma
10d
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
KarXT
Food and Drug Administration
Merck & Co.
Feedback